Drug Trial Radar · NCT07417735
SYS6010 Versus Chemotherapy in Locally Advanced or Metastatic/Recurrent Esophageal Squamous Cell Carcinoma
Last checked: Nov 19, 2026Latest source record: Feb 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
436
Planned (sponsor's estimate)
Start
Mar 18, 2026
Primary completion
Dec 31, 2028
Study completion Dec 31, 2029
Sponsor
- Lead sponsor
- CSPC Megalith Biopharmaceutical Co.,Ltd.Industry
- Sponsor type
- Industry
- First posted
- Feb 18, 2026
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is a randomized, Controlled, Open-Label, Multicenter Phase Ⅲ Study of SYS6010 vs Investigator's Choice Single-Agent Chemotherapy in Locally Advanced/Metastatic/Recurrent ESCC Patients with Failure of At Least One Line of Systemic Therapy
Conditions
- Locally Advanced/Metastatic/Recurrent ESCC
Interventions
SYS6010Drug
SYS6010 IV
Investigator's Choice of Chemotherapy (Irinotecan hydrochloride,Paclitaxel,Docetaxel)Drug
Investigator's choice of chemotherapy means the chemotherapy chosen by investigators/doctors to treat Locally Advanced/Metastatic/Recurrent ESCC, including Irinotecan hydrochloride(125 mg/m\^2 by IV on D1 and D8,3 weeks/cycle;or 150 \~180 mg/m\^2 by IV on D1,Q2W,4 weeks/cycle), Paclitaxel(175 mg/m\^2 by IV on D1,3 weeks/cycle;or 80 mg/m\^2 by IV on D1/D8/D15/D22,4 weeks/cycle;or 80 mg/m\^2 by IV on D1/D8/D15,4 weeks/cycle), or Docetaxel(75\~100 mg/m\^2 by IV on D1,3 weeks/cycle)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression Free Survival (PFS) Assessed by Blinded Independent Central Review(BICR) According to the RECIST 1.1 CriteriaTime frame: Up to 2 years
- Overall Survival (OS)Time frame: Up to 2 years
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.